ReportWire

Tag: Medical

  • New York City is working with a nonprofit to wipe out over $2 billion in medical debt for half a million residents

    New York City is working with a nonprofit to wipe out over $2 billion in medical debt for half a million residents

    [ad_1]

    New York City intends to wipe out more than $2 billion in medical debt for up to 500,000 residents, tackling a top cause of personal bankruptcy, Mayor Eric Adams announced Monday.

    The city is working with RIP Medical Debt, a nonprofit that buys medical debt in bulk from hospitals and debt collectors for pennies on the dollar. The group targets the debt of people with low incomes or financial hardships and then forgives the amounts.

    Under the program, the city will spend $18 million over three years.

    “For middle- and working-class New Yorkers, medical bills can be financially devastating,” Adams said as he announced the plan. “Working-class families often have to choose between paying their medical bills or some of the basic essentials that they need to go through life.”

    The mayor said medical debt is the No. 1 cause of bankruptcy in the United States, disproportionately burdening low-income households and people with inadequate insurance. He called the debt relief program the largest municipal initiative of its kind in the country, though RIP Medical Debt has worked with other municipalities.

    RIP Medical Debt president and CEO Allison Sesso said there will be no application process for the program. Relief recipients will be notified that their debt has been bought by a third party and erased.

    Though New York City is facing financial strains, Adams said the $18 million commitment over three years is a great investment for the city.

    “If you are able to … save $2 billion in debt, that $2 billion trickles down to those households, who are not going to fall into our safety net,” he said. “They’re not going to fall into our homeless system.”

    Subscribe to the CEO Daily newsletter to get the CEO perspective on the biggest headlines in business. Sign up for free.

    [ad_2]

    The Associated Press

    Source link

  • Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Congress Wealth Management LLC DE

    Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Congress Wealth Management LLC DE

    [ad_1]

    Congress Wealth Management LLC DE lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 28.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,643 shares of the medical research company’s stock after buying an additional 588 shares during the period. Congress Wealth Management LLC DE’s holdings in Thermo Fisher Scientific were worth $1,338,000 at the end of the most recent reporting period.

    A number of other institutional investors have also recently added to or reduced their stakes in TMO. Bornite Capital Management LP lifted its position in Thermo Fisher Scientific by 50.0% in the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock worth $17,719,000 after purchasing an additional 10,000 shares during the period. Fairfield Bush & CO. lifted its position in Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock worth $1,729,000 after purchasing an additional 36 shares during the period. Loomis Sayles & Co. L P lifted its position in shares of Thermo Fisher Scientific by 563.5% during the 1st quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after acquiring an additional 16,853 shares during the last quarter. Covestor Ltd lifted its position in shares of Thermo Fisher Scientific by 60.5% during the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 121 shares during the last quarter. Finally, Merit Financial Group LLC lifted its position in shares of Thermo Fisher Scientific by 3.6% during the 1st quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock valued at $395,000 after acquiring an additional 23 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

    Thermo Fisher Scientific Stock Down 0.3 %

    NYSE TMO opened at $544.32 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $609.85. The stock’s 50 day moving average is $502.69 and its two-hundred day moving average is $511.17. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $210.31 billion, a price-to-earnings ratio of 35.67, a PEG ratio of 3.27 and a beta of 0.81.

    Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Wednesday, October 25th. The medical research company reported $5.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.61 by $0.08. Thermo Fisher Scientific had a net margin of 13.68% and a return on equity of 18.88%. The company had revenue of $10.57 billion during the quarter, compared to analysts’ expectations of $10.60 billion. During the same quarter in the previous year, the company posted $5.08 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 1.0% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

    Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, November 14th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

    Thermo Fisher Scientific Announces Dividend

    The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 16th. Investors of record on Friday, December 15th will be given a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.17%.

    Insider Buying and Selling

    In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $454.41, for a total value of $4,544,100.00. Following the completion of the transaction, the chief executive officer now owns 131,175 shares in the company, valued at approximately $59,607,231.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

    Wall Street Analysts Forecast Growth

    TMO has been the topic of several recent analyst reports. Robert W. Baird reissued an “outperform” rating and set a $670.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Morgan Stanley decreased their price target on shares of Thermo Fisher Scientific from $640.00 to $600.00 and set an “overweight” rating for the company in a report on Tuesday, October 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Citigroup upped their price target on shares of Thermo Fisher Scientific from $530.00 to $575.00 and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Royal Bank of Canada decreased their price target on shares of Thermo Fisher Scientific from $657.00 to $579.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $597.53.

    View Our Latest Stock Report on Thermo Fisher Scientific

    Thermo Fisher Scientific Profile

    (Free Report)

    Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

    Featured Stories

    Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

    Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

    Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Scientists Find Clues About Why More Northern European Descendants Get MS

    Scientists Find Clues About Why More Northern European Descendants Get MS

    [ad_1]

    Findings from a project comparing modern DNA with samples from ancient human teeth and bones allowed scientists to find disease-linked genes following prehistoric migrations, tracing a path back to the Bronze Age Yamnaya people who probably carried the genetic mutation to protect the nomadic herders from infections carried by their livestock. What do you think?

    “Damn. I really wanted to blame my mother’s poor prenatal diet.”

    Gavin Perkins, Papal Understudy

    This Week’s Most Viral News: January 12, 2024

    “Are we positive ancient people weren’t designing viruses in labs?”

    Kara Courtwright, Systems Analyst

    “Haven’t Northern Europeans suffered enough?”

    Rodney Rabenbauer, Freelance Trucker

    [ad_2]

    Source link

  • IDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $43.00 by Analysts at Royal Bank of Canada

    IDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $43.00 by Analysts at Royal Bank of Canada

    [ad_1]

    IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price target upped by stock analysts at Royal Bank of Canada from $36.00 to $43.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target suggests a potential upside of 16.44% from the stock’s current price.

    Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of IDEAYA Biosciences from $35.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, November 30th. The Goldman Sachs Group boosted their price target on IDEAYA Biosciences from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Tuesday, September 12th. Wedbush reissued an “outperform” rating and issued a $43.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, November 8th. Finally, Guggenheim reduced their target price on IDEAYA Biosciences from $48.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $35.27.

    View Our Latest Research Report on IDYA

    IDEAYA Biosciences Price Performance

    Shares of NASDAQ IDYA opened at $36.93 on Wednesday. IDEAYA Biosciences has a one year low of $13.29 and a one year high of $37.25. The business’s 50-day moving average price is $32.61 and its two-hundred day moving average price is $28.02. The company has a market capitalization of $2.38 billion, a P/E ratio of -18.94 and a beta of 0.82.

    IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.03. The business had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $8.14 million. IDEAYA Biosciences had a negative return on equity of 24.39% and a negative net margin of 439.48%. The company’s revenue was up 128.6% on a year-over-year basis. On average, equities analysts anticipate that IDEAYA Biosciences will post -1.95 EPS for the current year.

    Insider Buying and Selling

    In other IDEAYA Biosciences news, insider Jason Throne sold 5,163 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $30.09, for a total value of $155,354.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other IDEAYA Biosciences news, insider Jason Throne sold 5,163 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $30.09, for a total value of $155,354.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yujiro S. Hata sold 75,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.03, for a total value of $2,627,250.00. Following the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $23,746,381.61. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,163 shares of company stock valued at $2,850,605. 5.00% of the stock is owned by company insiders.

    Hedge Funds Weigh In On IDEAYA Biosciences

    A number of hedge funds have recently made changes to their positions in the business. Exchange Traded Concepts LLC increased its stake in IDEAYA Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after acquiring an additional 1,219 shares during the period. Vanguard Group Inc. grew its stake in shares of IDEAYA Biosciences by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,971,497 shares of the company’s stock valued at $80,171,000 after purchasing an additional 141,844 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of IDEAYA Biosciences in the 3rd quarter worth approximately $944,000. Citigroup Inc. lifted its position in shares of IDEAYA Biosciences by 3.7% during the 3rd quarter. Citigroup Inc. now owns 55,254 shares of the company’s stock worth $1,491,000 after buying an additional 1,967 shares during the period. Finally, American Century Companies Inc. boosted its stake in IDEAYA Biosciences by 36.7% in the 3rd quarter. American Century Companies Inc. now owns 39,655 shares of the company’s stock valued at $1,070,000 after buying an additional 10,640 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

    IDEAYA Biosciences Company Profile

    (Get Free Report)

    IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

    Further Reading

    Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

    Receive News & Ratings for IDEAYA Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEAYA Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Biden Announces Plans For Extra PlayStation 5 Controller In Case Someone Visits Nation

    Biden Announces Plans For Extra PlayStation 5 Controller In Case Someone Visits Nation

    [ad_1]

    Read more…

    [ad_2]

    Source link

  • Kneel Young

    Kneel Young

    [ad_1]

    Read more…

    [ad_2]

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by Burke & Herbert Bank & Trust Co.

    Johnson & Johnson (NYSE:JNJ) Shares Sold by Burke & Herbert Bank & Trust Co.

    [ad_1]

    Burke & Herbert Bank & Trust Co. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,909 shares of the company’s stock after selling 5,164 shares during the quarter. Johnson & Johnson accounts for approximately 2.9% of Burke & Herbert Bank & Trust Co.’s investment portfolio, making the stock its 6th biggest holding. Burke & Herbert Bank & Trust Co.’s holdings in Johnson & Johnson were worth $3,568,000 at the end of the most recent quarter.

    Several other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after buying an additional 2,688,798 shares during the period. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.1% during the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock worth $23,476,323,000 after buying an additional 1,568,633 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock worth $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

    Analyst Ratings Changes

    Several brokerages recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating on shares of Johnson & Johnson in a report on Monday, December 18th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 target price on shares of Johnson & Johnson in a report on Friday, December 1st. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $168.75.

    Read Our Latest Stock Report on JNJ

    Johnson & Johnson Stock Up 0.2 %

    Shares of NYSE JNJ opened at $156.61 on Friday. The company’s 50-day simple moving average is $152.48 and its 200-day simple moving average is $159.60. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $180.93. The firm has a market cap of $377.00 billion, a price-to-earnings ratio of 11.63, a price-to-earnings-growth ratio of 3.20 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The business had revenue of $21.35 billion for the quarter, compared to analyst estimates of $21 billion. Equities analysts predict that Johnson & Johnson will post 9.96 EPS for the current fiscal year.

    Johnson & Johnson Announces Dividend

    The business also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were given a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 35.34%.

    Johnson & Johnson Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Further Reading

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Acquired by Kingdom Financial Group LLC.

    Johnson & Johnson (NYSE:JNJ) Shares Acquired by Kingdom Financial Group LLC.

    [ad_1]

    Kingdom Financial Group LLC. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 258.0% during the third quarter, Holdings Channel reports. The fund owned 9,268 shares of the company’s stock after purchasing an additional 6,679 shares during the quarter. Johnson & Johnson comprises 1.4% of Kingdom Financial Group LLC.’s portfolio, making the stock its 17th biggest holding. Kingdom Financial Group LLC.’s holdings in Johnson & Johnson were worth $1,443,000 as of its most recent SEC filing.

    A number of other large investors have also made changes to their positions in the stock. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $27,000. Atlantic Private Wealth LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $32,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $37,000. VitalStone Financial LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth about $48,000. Finally, Horizons Wealth Management lifted its stake in shares of Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

    Johnson & Johnson Trading Up 0.1 %

    NYSE:JNJ opened at $156.35 on Thursday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $180.93. The firm has a market capitalization of $376.38 billion, a P/E ratio of 11.61, a P/E/G ratio of 3.18 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. The business has a 50 day simple moving average of $152.40 and a 200 day simple moving average of $159.62.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The business had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. Equities research analysts predict that Johnson & Johnson will post 9.96 EPS for the current year.

    Johnson & Johnson Dividend Announcement

    The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st were given a dividend of $1.19 per share. The ex-dividend date was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

    Analysts Set New Price Targets

    Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Monday, December 18th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Raymond James dropped their target price on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Finally, HSBC initiated coverage on Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $168.75.

    Get Our Latest Research Report on Johnson & Johnson

    About Johnson & Johnson

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Featured Articles

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Head-To-Head Review: Zoetis (NYSE:ZTS) vs. Marijuana Company of America (OTCMKTS:MCOA) – Medical Marijuana Program Connection

    Head-To-Head Review: Zoetis (NYSE:ZTS) vs. Marijuana Company of America (OTCMKTS:MCOA) – Medical Marijuana Program Connection

    [ad_1]

    Zoetis (NYSE:ZTS – Get Free Report) and Marijuana Company of America (OTCMKTS:MCOA – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

    Earnings and Valuation

    This table compares Zoetis and Marijuana Company of America’s top-line revenue, earnings per share and valuation.

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
    Zoetis $8.37 billion 10.69 $2.11 billion $4.92 39.63
    Marijuana Company of America N/A N/A N/A N/A N/A

    Zoetis has higher revenue and earnings than Marijuana Company of America.

    Profitability

    Want More Great Investing Ideas?

    This table compares Zoetis and Marijuana Company of America’s net margins, return on equity and return on assets.

    Net Margins Return on Equity Return on Assets
    Zoetis 27.24% 52.22% 17.17%
    Marijuana Company of America N/A N/A N/A

    Institutional & Insider Ownership

    89.5% of Zoetis shares are held by institutional investors. 0.1% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

    Analyst Recommendations

    This is a summary of recent ratings and price targets for Zoetis and Marijuana Company of America, as provided by…

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by M&R Capital Management Inc.

    Johnson & Johnson (NYSE:JNJ) Shares Sold by M&R Capital Management Inc.

    [ad_1]

    M&R Capital Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,635 shares of the company’s stock after selling 811 shares during the quarter. Johnson & Johnson makes up about 1.1% of M&R Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest holding. M&R Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,837,000 at the end of the most recent reporting period.

    Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $4,609,399,000. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC boosted its holdings in shares of Johnson & Johnson by 161,420.2% during the second quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after acquiring an additional 7,271,978 shares during the period. Finally, Providence Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares during the period. 68.40% of the stock is owned by institutional investors.

    Wall Street Analyst Weigh In

    JNJ has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 price target on shares of Johnson & Johnson in a report on Friday, December 1st. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 26th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.75.

    Read Our Latest Stock Analysis on Johnson & Johnson

    Johnson & Johnson Price Performance

    JNJ stock opened at $156.46 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a one year low of $144.95 and a one year high of $180.93. The firm has a market capitalization of $376.64 billion, a PE ratio of 11.62, a P/E/G ratio of 3.17 and a beta of 0.57. The firm has a 50-day moving average of $152.51 and a two-hundred day moving average of $159.79.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The company had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. On average, analysts forecast that Johnson & Johnson will post 9.97 earnings per share for the current year.

    Johnson & Johnson Announces Dividend

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is 35.34%.

    Johnson & Johnson Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Montchanin Asset Management LLC Sells 400 Shares of Merck & Co., Inc. (NYSE:MRK)

    Montchanin Asset Management LLC Sells 400 Shares of Merck & Co., Inc. (NYSE:MRK)

    [ad_1]

    Montchanin Asset Management LLC reduced its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,733 shares of the company’s stock after selling 400 shares during the quarter. Montchanin Asset Management LLC’s holdings in Merck & Co., Inc. were worth $546,000 as of its most recent SEC filing.

    A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wahed Invest LLC raised its position in Merck & Co., Inc. by 0.3% in the 1st quarter. Wahed Invest LLC now owns 32,439 shares of the company’s stock worth $3,451,000 after purchasing an additional 91 shares during the period. Richard W. Paul & Associates LLC raised its position in Merck & Co., Inc. by 1.0% in the 2nd quarter. Richard W. Paul & Associates LLC now owns 9,389 shares of the company’s stock worth $1,083,000 after purchasing an additional 94 shares during the period. Financial Gravity Asset Management Inc. raised its position in Merck & Co., Inc. by 32.2% in the 2nd quarter. Financial Gravity Asset Management Inc. now owns 386 shares of the company’s stock worth $12,730,000 after purchasing an additional 94 shares during the period. Versant Capital Management Inc raised its position in Merck & Co., Inc. by 11.4% in the 2nd quarter. Versant Capital Management Inc now owns 926 shares of the company’s stock worth $107,000 after purchasing an additional 95 shares during the period. Finally, Providence Wealth Advisors LLC raised its position in Merck & Co., Inc. by 1.0% in the 1st quarter. Providence Wealth Advisors LLC now owns 9,711 shares of the company’s stock worth $1,106,000 after purchasing an additional 96 shares during the period. 74.59% of the stock is owned by hedge funds and other institutional investors.

    Insider Transactions at Merck & Co., Inc.

    In other news, EVP Richard R. Deluca sold 43,823 shares of Merck & Co., Inc. stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the sale, the executive vice president now directly owns 111,764 shares in the company, valued at $11,738,572.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Richard R. Deluca sold 43,823 shares of Merck & Co., Inc. stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the sale, the executive vice president now directly owns 111,764 shares in the company, valued at $11,738,572.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Jacobus Oosthuizen sold 2,081 shares of Merck & Co., Inc. stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $102.38, for a total transaction of $213,052.78. Following the sale, the insider now owns 18,191 shares of the company’s stock, valued at $1,862,394.58. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

    Merck & Co., Inc. Price Performance

    Shares of MRK opened at $104.36 on Wednesday. The company has a market cap of $264.45 billion, a price-to-earnings ratio of 57.98, a price-to-earnings-growth ratio of 8.78 and a beta of 0.34. Merck & Co., Inc. has a twelve month low of $96.36 and a twelve month high of $119.65. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average of $103.07 and a two-hundred day moving average of $106.71.

    Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Thursday, October 26th. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.19. The company had revenue of $16 billion during the quarter, compared to the consensus estimate of $15.30 billion. Merck & Co., Inc. had a net margin of 7.77% and a return on equity of 18.26%. Merck & Co., Inc.’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm earned $1.85 earnings per share. As a group, analysts predict that Merck & Co., Inc. will post 1.37 earnings per share for the current fiscal year.

    Merck & Co., Inc. Increases Dividend

    The company also recently announced a quarterly dividend, which will be paid on Monday, January 8th. Shareholders of record on Friday, December 15th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.95%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 162.22%.

    Wall Street Analysts Forecast Growth

    MRK has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, November 29th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, November 9th. They set a “buy” rating and a $115.00 target price on the stock. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and set a $132.00 target price on the stock in a research report on Friday, October 27th. Truist Financial reaffirmed a “buy” rating and set a $122.00 target price on shares of Merck & Co., Inc. in a research report on Friday, October 6th. Finally, Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $115.00 to $118.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $125.14.

    View Our Latest Stock Report on Merck & Co., Inc.

    Merck & Co., Inc. Profile

    (Free Report)

    Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

    Read More

    Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

    Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • When the White in Your Eyes Is Not Quite White, Should You Worry?

    When the White in Your Eyes Is Not Quite White, Should You Worry?

    [ad_1]

    Why are the whites of my eyes a different color?When the White in Your Eyes Is Not Quite White,…

    [ad_2]

    Source link

  • Mirae Asset Global Investments Co. Ltd. Purchases 640 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

    Mirae Asset Global Investments Co. Ltd. Purchases 640 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

    [ad_1]

    Mirae Asset Global Investments Co. Ltd. grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 3.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,324 shares of the company’s stock after purchasing an additional 640 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Amphastar Pharmaceuticals were worth $1,053,000 as of its most recent filing with the SEC.

    A number of other hedge funds have also bought and sold shares of the company. Point72 Middle East FZE bought a new stake in Amphastar Pharmaceuticals in the fourth quarter worth approximately $50,000. Pacer Advisors Inc. bought a new stake in Amphastar Pharmaceuticals in the second quarter valued at $59,000. Point72 Hong Kong Ltd acquired a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at about $74,000. Tower Research Capital LLC TRC boosted its position in shares of Amphastar Pharmaceuticals by 206.9% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,998 shares of the company’s stock worth $75,000 after purchasing an additional 1,347 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in shares of Amphastar Pharmaceuticals by 114.4% in the 1st quarter. Captrust Financial Advisors now owns 2,770 shares of the company’s stock valued at $99,000 after buying an additional 1,478 shares during the period. Institutional investors own 65.09% of the company’s stock.

    Amphastar Pharmaceuticals Price Performance

    AMPH stock opened at $57.92 on Monday. The company has a market capitalization of $2.77 billion, a P/E ratio of 22.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.92. Amphastar Pharmaceuticals, Inc. has a 52-week low of $27.58 and a 52-week high of $67.66. The business has a 50-day simple moving average of $49.34 and a two-hundred day simple moving average of $51.83. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.68 and a current ratio of 2.11.

    Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its quarterly earnings results on Wednesday, November 8th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.41. Amphastar Pharmaceuticals had a return on equity of 26.68% and a net margin of 22.50%. The business had revenue of $180.56 million during the quarter, compared to analyst estimates of $170.65 million. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.91 EPS for the current fiscal year.

    Wall Street Analyst Weigh In

    AMPH has been the topic of several recent research reports. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 21st. Bank of America began coverage on Amphastar Pharmaceuticals in a report on Friday, November 17th. They issued a “neutral” rating and a $63.00 target price on the stock. Finally, Piper Sandler boosted their price target on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research note on Wednesday, August 9th.

    Check Out Our Latest Stock Analysis on Amphastar Pharmaceuticals

    Insider Activity

    In related news, CFO William J. Peters sold 60,743 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the transaction, the chief financial officer now directly owns 101,360 shares in the company, valued at $5,245,380. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $52.50, for a total value of $262,500.00. Following the transaction, the director now owns 35,895 shares of the company’s stock, valued at $1,884,487.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO William J. Peters sold 60,743 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the completion of the transaction, the chief financial officer now owns 101,360 shares of the company’s stock, valued at approximately $5,245,380. The disclosure for this sale can be found here. Insiders sold a total of 70,743 shares of company stock worth $3,674,930 over the last quarter. Insiders own 28.40% of the company’s stock.

    Amphastar Pharmaceuticals Company Profile

    (Free Report)

    Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

    Featured Stories

    Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

    Receive News & Ratings for Amphastar Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Mugger Took Self-Defense Classes Too

    Mugger Took Self-Defense Classes Too

    [ad_1]

    Read more…

    [ad_2]

    Source link

  • How To Eat Healthy In Just 3 Bites

    How To Eat Healthy In Just 3 Bites

    [ad_1]

    Eating right is a great way to boost your immune system as well as your mental health, but changing your habits and sticking to a regimen can be daunting. Fortunately, you don’t have to do any of that hard work, if you follow The Onion’s tips for eating healthy in just three bites.

    [ad_2]

    Source link

  • Envestnet Asset Management Inc. Has $6.63 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

    Envestnet Asset Management Inc. Has $6.63 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

    [ad_1]

    Envestnet Asset Management Inc. cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 79.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 78,989 shares of the medical equipment provider’s stock after selling 312,545 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Lantheus were worth $6,629,000 as of its most recent filing with the Securities and Exchange Commission.

    Other hedge funds and other institutional investors have also bought and sold shares of the company. Altshuler Shaham Ltd acquired a new position in Lantheus in the 2nd quarter valued at $27,000. SJS Investment Consulting Inc. boosted its holdings in Lantheus by 6,460.0% in the 2nd quarter. SJS Investment Consulting Inc. now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 323 shares during the period. AlphaMark Advisors LLC boosted its holdings in Lantheus by 456.3% in the 1st quarter. AlphaMark Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 365 shares during the period. Harbor Investment Advisory LLC bought a new stake in Lantheus in the 2nd quarter valued at $38,000. Finally, Macquarie Group Ltd. boosted its holdings in Lantheus by 21.7% in the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 108 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

    Wall Street Analysts Forecast Growth

    A number of brokerages have weighed in on LNTH. Mizuho reissued a “buy” rating and issued a $125.00 price target on shares of Lantheus in a report on Wednesday, October 4th. William Blair began coverage on shares of Lantheus in a report on Friday, September 29th. They issued an “outperform” rating for the company. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Monday, November 6th. B. Riley reissued a “buy” rating and issued a $113.00 price target on shares of Lantheus in a report on Tuesday, October 3rd. Finally, JMP Securities reduced their price objective on shares of Lantheus from $130.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, November 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus currently has an average rating of “Buy” and an average target price of $115.00.

    Check Out Our Latest Research Report on LNTH

    Insider Transactions at Lantheus

    In other news, President Paul Blanchfield sold 408 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the completion of the transaction, the president now directly owns 90,067 shares of the company’s stock, valued at approximately $5,953,428.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, CEO Mary Anne Heino sold 11,780 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $63.72, for a total value of $750,621.60. Following the transaction, the chief executive officer now directly owns 317,687 shares in the company, valued at $20,243,015.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, President Paul Blanchfield sold 408 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the completion of the transaction, the president now owns 90,067 shares in the company, valued at $5,953,428.70. The disclosure for this sale can be found here. In the last three months, insiders sold 15,783 shares of company stock valued at $1,015,296. Company insiders own 1.50% of the company’s stock.

    Lantheus Price Performance

    NASDAQ:LNTH opened at $68.20 on Friday. The company has a 50-day moving average of $66.53 and a 200-day moving average of $77.25. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of 47.69 and a beta of 0.66. Lantheus Holdings, Inc. has a 52 week low of $47.46 and a 52 week high of $100.85. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.05 and a current ratio of 5.37.

    Lantheus Profile

    (Free Report)

    Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

    Featured Articles

    Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).

    Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

    Receive News & Ratings for Lantheus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lantheus and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Men Explain Why They Prefer AI Girlfriends

    Men Explain Why They Prefer AI Girlfriends

    [ad_1]

    Read more…

    [ad_2]

    Source link

  • Vision Capital Management Inc. Has $8.67 Million Stake in Johnson & Johnson (NYSE:JNJ)

    Vision Capital Management Inc. Has $8.67 Million Stake in Johnson & Johnson (NYSE:JNJ)

    [ad_1]

    Vision Capital Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 52,406 shares of the company’s stock after selling 326 shares during the quarter. Johnson & Johnson makes up 1.5% of Vision Capital Management Inc.’s investment portfolio, making the stock its 20th largest holding. Vision Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,674,000 as of its most recent filing with the SEC.

    Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Farmers & Merchants Investments Inc. lifted its holdings in Johnson & Johnson by 1.2% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 164,235 shares of the company’s stock worth $27,184,000 after purchasing an additional 1,954 shares during the last quarter. FIDELIS iM LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $207,000. Pursue Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $881,000. Choate Investment Advisors lifted its holdings in Johnson & Johnson by 16.6% in the 2nd quarter. Choate Investment Advisors now owns 79,544 shares of the company’s stock worth $13,166,000 after purchasing an additional 11,330 shares during the last quarter. Finally, BDO Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 3.5% in the 2nd quarter. BDO Wealth Advisors LLC now owns 16,998 shares of the company’s stock worth $2,813,000 after purchasing an additional 576 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

    Wall Street Analyst Weigh In

    Several brokerages have commented on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Morgan Stanley dropped their price target on Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Atlantic Securities lifted their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Finally, TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $169.19.

    Read Our Latest Analysis on Johnson & Johnson

    Johnson & Johnson Stock Performance

    Shares of NYSE:JNJ opened at $145.60 on Monday. The business’s fifty day moving average price is $158.90 and its two-hundred day moving average price is $161.94. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04. The stock has a market capitalization of $378.41 billion, a price-to-earnings ratio of 10.81, a price-to-earnings-growth ratio of 2.94 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

    Johnson & Johnson Announces Dividend

    The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 35.34%.

    About Johnson & Johnson

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Crouzon Syndrome Patients Showcase Successful Plastic Correction Outcomes

    Crouzon Syndrome Patients Showcase Successful Plastic Correction Outcomes

    [ad_1]

    Plastic surgery for correction of Crouzon Syndrome in a young boy ❤👏Crouzon Syndrome Patients…

    [ad_2]

    Source link

  • Concerning Study Finds 1 In 10 Americans Lack Access To Adequate Food Eating Challenges

    Concerning Study Finds 1 In 10 Americans Lack Access To Adequate Food Eating Challenges

    [ad_1]

    Read more…

    [ad_2]

    Source link